Browsing Tag
Theravance Biopharma
3 posts
Theravance Biopharma (NASDAQ: TBPH) drops rare disease drug after Phase 3 failure triggers strategic review
Theravance Biopharma drops its rare disease drug after a Phase 3 failure. Explore what this means for NASDAQ: TBPH and biotech investors.
Theravance completes enrollment in Phase 3 CYPRESS trial for ampreloxetine in MSA-related nOH
Theravance completes Phase 3 enrollment for ampreloxetine in MSA-related nOH. Topline data expected in Q1 2026. Could this be a rare disease breakthrough?
Theravance Biopharma cashes out remaining Trelegy royalties in $225m deal with GSK
Theravance Biopharma sells Trelegy royalties to GSK for $225M, unlocking shareholder value and reinforcing its focus on YUPELRI and ampreloxetine.